Short Interest in Pharming Group (NASDAQ:PHAR) Declines By 29.3%

Pharming Group (NASDAQ:PHAR) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 5,300 shares, a decline of 29.3% from the January 31st total of 7,500 shares. Based on an average daily volume of 6,600 shares, the short-interest ratio is presently 0.8 days.

Analysts Set New Price Targets

PHAR has been the topic of a number of research reports. Jefferies Financial Group assumed coverage on shares of Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, December 17th.

Pharming Group Stock Down 6.7 %

NASDAQ:PHAR traded down $0.62 during mid-day trading on Wednesday, hitting $8.63. The stock had a trading volume of 10,713 shares, compared to its average volume of 5,950. Pharming Group has a twelve month low of $6.65 and a twelve month high of $11.94. The stock has a 50-day simple moving average of $9.29 and a two-hundred day simple moving average of $8.56. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $587.11 million, a PE ratio of -33.19 and a beta of -0.10.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.